Monday, July 24, 2000
Screening is a rate limiting step for companies doing directed evolution to produce enzyme therapeutics and other products, because the process requires them to conduct the most complex assays possible at the smallest volumes possible to keep costs down. The ideal is to have a cell-based system that closely mimics real life. But where this is not possible, screening specialist Evotec BioSystems AG believes that its new spinout, Direvo Biotech AG, has a good alternative.
Direvo (Goettingen, Germany) will apply mutation and recombination techniques to develop improved enzymes for therapeutic and industrial applications. Evotec (NMarkt:EVT, Hamburg, Germany) will own 65 percent of the new company.